The company’s share price fell $2.56 on the day the FDA warning went public, closing at $33.19. Regulators allege that Medline failed to adhere to Current Good Manufacturing Practice regulations for finished pharmaceuticals, specifically noting a lack of thorough investigation into product failures. Pomerantz LLP is now reviewing whether these regulatory lapses constitute unlawful business practices or securities fraud that harmed shareholders. Investors impacted by the decline are encouraged to contact Danielle Peyton at the firm to discuss potential participation in class action litigation.
Medline Industries Faces Securities Fraud Investigation
A 7.16% drop in Medline Industries’ stock price has triggered a formal investigation by Pomerantz LLP into potential securities fraud. The inquiry follows a June 2, 2026, U.S. Food and Drug Administration warning letter citing significant violations of manufacturing regulations and failures to investigate unexplained batch discrepancies at the firm.
Comments (0)
No comments yet. Be the first!